Onsdag 15 Januari | 08:06:45 Europe / Stockholm

Svenska | English

Oculis Holding

Beskrivning

Land	Schweiz
Lista	Mid Cap Iceland
Sektor	Hälsovård
Industri	Bioteknik

Oculis Holding är specialiserade inom bioteknik. Bolaget bedriver forskning och utveckling inom topikala behandlingar för ögonsjukdomar. Exempel på specialistområden inkluderar diabetiskt makulaödem, bahandlingar för torra ögon och akut optisk neurit. Störst verksamhet återfinns inom Europa, där forskning bedrivs i egen regi men även via samarbetspartners. Bolaget har sitt huvudkontor i Zug, Schweiz.

Filter

År

Typ

Språk

Rensa

2025-01-06 09:53:25 Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential First-in-Class Neuroprotective Therapy 2480,00 ISK | +0,40%

2025-01-06 09:47:00 Oculis tilkynnir um jákvæðar niðurstöður úr fasa 2 ACUITY rannsóknar á OCS-05 við sjóntaugabólgu; aðalviðmiði um öryggi náð auk lykilviðmiða um virkni sem opnar á þróun sem mögulegt fyrsta lyf sinnar tegundar á sviði taugaverndandi meðferða 2480,00 ISK | +0,40%

2025-01-06 09:47:00 Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential First-in-Class Neuroprotective Therapy 2480,00 ISK | +0,40%

2025-01-04 00:48:20 Oculis Publishes Notification of Major Changes in Voting Rights 2470,00 ISK | +2,07%

2024-12-06 22:00:00 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities 2140,00 ISK | 0,00%

2024-11-29 10:00:00 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated 2220,00 ISK | -0,89%

2024-11-27 10:15:47 Oculis Publishes Notification of Transaction by Person Discharging Managerial Responsibilities 2220,00 ISK | +4,72%

2024-11-13 10:00:00 Oculis to Present at the Stifel 2024 Healthcare Conference 2100,00 ISK | -2,78%

2024-11-07 10:00:00 Oculis Reports Q3 2024 Financial Results and Provides Company Updates 2330,00 ISK | -4,51%

2024-11-07 10:00:00 Oculis birtir uppgjör fyrir þriðja ársfjórðung 2024 og kynnir nýjustu áfanga í rekstri félagsins 2330,00 ISK | -4,51%

2024-11-07 10:00:00 Oculis Reports Q3 2024 Financial Results and Provides Company Updates 2330,00 ISK | -4,51%

2024-10-21 19:04:57 Oculis Accelerates Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema and Expands its DIAMOND Program Committees 2120,00 ISK | +9,84%

2024-10-21 10:00:00 Oculis Accelerates Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema and Expands its DIAMOND Program Committees 2120,00 ISK | +9,84%

2024-10-15 10:00:00 Oculis’ DIAMOND Phase 3 Program in Diabetic Macular Edema to be Presented at Innovate Retina and Eyecelerator 2024 1960,00 ISK | -1,01%

2024-10-02 10:00:00 Oculis Announces Appointment of Daniel S. Char as Chief Legal Officer 1670,00 ISK | +1,83%

2024-09-19 19:00:00 Oculis and EURETINA Announce the Winner of the Inaugural Ramin Tadayoni Award 1630,00 ISK | -0,61%

2024-08-29 10:00:00 Oculis to Present at Upcoming September Investor Conferences 1680,00 ISK | 0,00%

2024-08-27 22:00:00 Oculis Publishes Consolidated Q2 Financial Statements and MD&A 1650,00 ISK | +1,85%

2024-08-27 10:00:00 Oculis birtir uppgjör fyrir annan ársfjórðung 2024 og kynnir nýjustu áfanga í rekstri félagsins 1650,00 ISK | +1,85%

2024-08-27 10:00:00 Oculis Reports Q2 Financial Results and Provides Recent Company Update 1650,00 ISK | +1,85%

2024-08-27 10:00:00 Oculis Reports Q2 2024 Financial Results and Provides Recent Company Update 1650,00 ISK | +1,85%

2024-08-15 14:00:00 Oculis Appoints Sharon Klier, M.D., M.S., M.P.H. as Chief Development Officer 1640,00 ISK | 0,00%

2024-07-30 22:10:00 Oculis to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference 1600,00 ISK | 0,00%

2024-06-27 12:30:57 Oculis and EURETINA Announces the Ramin Tadayoni Award 1665,00 ISK | +0,30%

2024-06-10 11:00:00 Oculis kynnir jákvæðar niðurstöður úr fasa 2b RELIEF-rannsókn með Licaminlimab, hannað til að umbylta meðferð augnþurrks með nákvæmnislyfjameðferð 1640,00 ISK | -1,20%

2024-06-10 11:00:00 Oculis Announces Positive Topline Results of Phase 2b RELIEF Trial with Licaminlimab, Designed to Transform the Treatment Paradigm of Dry Eye Disease with a Precision Medicine Strategy 1640,00 ISK | -1,20%

2024-06-04 19:47:10 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities 1620,00 ISK | -0,31%

2024-05-30 10:00:00 Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board 1630,00 ISK | 0,00%

2024-05-30 10:00:00 Oculis birtir niðurstöður aðalfundar 2024 og tilkynnir um skipanir í stjórn og vísindaráð 1630,00 ISK | 0,00%

2024-05-30 10:00:00 Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board 1630,00 ISK | 0,00%

2024-05-17 22:30:00 Oculis updates share capital for its existing at-the-market offering program 1670,00 ISK | -0,60%

2024-05-08 22:10:00 Oculis Reports Q1 2024 Financial Results and Provides Company Updates 1750,00 ISK | -0,57%

2024-05-07 22:05:00 Oculis Publishes Invitation to the Annual General Meeting 1760,00 ISK | -2,22%

2024-04-29 22:05:00 Oculis Publishes Invitation to the Annual General Meeting 1730,00 ISK | +1,17%

2024-04-22 15:27:46 Oculis Announces Closing of Registered Direct Offering and Commencement of Trading on Nasdaq Iceland Main Market

2024-04-22 14:34:24 Oculis Announces Closing of Registered Direct Offering and Commencement of Trading on Nasdaq Iceland Main Market

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Oculis Holding

Beskrivning

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden